United States Patent 9,289,442: Scope, Claim-by-Claim Coverage, and Patent Landscape
US Patent 9,289,442 claims an anhydrous topical pharmaceutical composition built around a specific combination of a film-forming polymer, high-level alcohol solvent, humectant, emollient/silicone, and a diazeniumdiolated co-condensed silica particle (DCD silica). The patent’s practical scope is defined by (1) tight quantitative ranges for each excipient class, (2) particle-generation constraints for the DCD silica, and (3) downstream use in treatment methods for dermatologic conditions such as acne.
What does claim 1 cover, and what does it require (hard structural scope)?
Claim 1: Composition definition
Claim 1 requires an anhydrous (water-free) topical formulation comprising all of the following components at specified weight ranges (percent by weight of the anhydrous topical pharmaceutical composition):
| Element required by claim 1 |
Claim language (weight range) |
Practical meaning for scope |
| Hydroxypropyl cellulose (HPC) |
0.1% to 15% |
Polymer thickener/film former in an anhydrous vehicle |
| Ethyl alcohol or isopropyl alcohol |
45% to 95% |
Dominant volatile solvent system; composition is defined as alcohol-based |
| Hexylene glycol |
1% to 20% |
Humectant/co-solvent |
| Cyclomethicone |
0.5% to 15% |
Silicone solvent/emollient component |
| Diazeniumdiolated co-condensed silica particle (DCD silica) |
0.1% to 40% |
Active/functional component based on diazeniumdiolated silica particles |
All five ingredients are mandatory in the claimed ranges. A design-around that omits any one required component (or places it outside the stated ranges) avoids literal infringement.
Key claim 1 scope constraints
- “Anhydrous” is a claim limitation. If measurable water is present above what the patent’s “anhydrous” concept allows, literal scope can fail. From an infringement standpoint, formulation characterization is decisive.
- Alcohol content is the dominant structural feature. The vehicle is forced into a high-alcohol band (45% to 95%). That sharply limits coverage of gel/cream vehicles where alcohol is not the principal continuous phase.
- DCD silica is the signature differentiator. The claim is not simply “a topical nitric oxide donor” in general terms; it specifically requires diazeniumdiolated co-condensed silica particles at 0.1% to 40%.
How narrow are dependent claims, and where do they add enforceable constraints?
Claim 2: Particle size limitation for DCD silica
- DCD co-condensed silica particle has mean particle size < 10 µm.
This adds a formulation/process-adjacent limitation. Two implications for landscape and freedom-to-operate:
- A competitor using larger DCD silica particles can avoid literal claim 2.
- If claim 1 is infringed but claim 2 is not, the dependent claim 2 coverage is narrower; independent claim 1 remains the fallback.
Claim 3-5: Packaging and shelf life performance
Claim 3 requires a performance attribute tied to packaging:
- Claim 3: packaged composition has shelf life at least four weeks.
- Claim 4: shelf life is under refrigerated conditions.
- Claim 5: shelf life is at least 52 weeks.
These constraints matter because they do not just define composition; they define product stability in a packaged form and, for claim 4, the temperature regime.
For infringement risk, two scenarios drive exposure:
- If a marketed product uses the claimed composition but does not meet the shelf-life threshold, it can avoid dependent claims 3-5.
- If it meets the thresholds, packaging and stability documentation become relevant.
Claims 6-7: Use claims for dermatologic treatment
- Claim 6: method of treating dermatological condition by applying claim 1 composition to skin.
- Claim 7: dermatological condition comprises acne.
These are classic method-of-use hooks. Even if a composition is used non-therapeutically (cosmetic-only positioning), method claims can still be implicated if the intended use aligns with the claimed treatment.
What does the claim set imply about the formulation technology (scope drivers)?
1) The claimed active system is particle-based NO-release chemistry
The unique term is “diazeniumdiolated co-condensed silica particle.” Diazeniumdiolated silica systems are a known class of nitric oxide (NO) donor materials, typically designed for sustained NO release upon exposure to biological conditions. The “co-condensed silica” language indicates a specific silica synthesis architecture (co-condensation forming the pore/structure prior to diazeniumdiolation).
In practical infringement terms:
- The patent’s scope likely centers on formulations using this class of DCD silica as the NO donor rather than other NO donors (e.g., S-nitrosothiols, N-diazeniumdiolate small molecules, or different nanoparticle supports).
2) Vehicle constraints tie the patent to alcohol-forward delivery
A topical anhydrous alcohol vehicle at 45% to 95% is a strong delimiting feature. It likely correlates to:
- Rapid drying,
- Enhanced dispersion of silica particles,
- Barrier film formation when paired with HPC and cyclomethicone.
3) The formulation is not “any topical HPC-alcohol gel”
HPC is present only in a specified range and must coexist with hexylene glycol and cyclomethicone in their ranges alongside the DCD silica particle.
That structure reduces the chance that a superficially similar acne alcohol spray without the DCD silica would fall within the literal claim.
Where is the patent likely vulnerable (and where it stays strong)?
Strong points for enforceability
- Hard quantitative ranges (HPC, alcohol, hexylene glycol, cyclomethicone, DCD silica) make claim mapping straightforward when a formulation matches.
- Signature ingredient (diazeniumdiolated co-condensed silica) provides a narrow active-technology anchor.
- Dependent particle-size and shelf-life constraints enable additional layers of protection for products designed for specific stability and particle metrics.
Potential vulnerability
- The enforceable scope of claim 1 is limited to formulations that are simultaneously:
- anhydrous,
- alcohol-forward within the specified band,
- contain the required excipients at required ranges,
- and include DCD co-condensed silica at the specified range.
- Competitors can reduce risk by:
- using different NO donor particle chemistries or supports,
- changing solvent system outside alcohol bands,
- shifting excipient levels outside ranges,
- using different particle size distributions to avoid claim 2,
- or failing shelf-life/packaging conditions relevant to claims 3-5.
Claim mapping scenarios (what would likely infringe vs avoid)
Likely literal infringement of claim 1
A topical anhydrous composition that includes:
- HPC at 0.1%-15%,
- ethanol and/or isopropanol at 45%-95%,
- hexylene glycol at 1%-20%,
- cyclomethicone at 0.5%-15%,
- DCD co-condensed silica at 0.1%-40%,
- and meets anhydrous condition,
would map directly to claim 1.
If acne treatment is indicated by labeling or method instruction, claims 6-7 also become relevant.
Likely avoidance strategies
- Replace DCD co-condensed silica with another NO donor category (NO donor not “diazeniumdiolated co-condensed silica”).
- Use alcohol outside 45%-95% (e.g., a lower-alcohol lotion or an alcohol-free emulsion).
- Shift DCD silica content below 0.1% or above 40%.
- Use DCD silica particles with mean size 10 µm or more (to avoid claim 2).
- Market or store a packaged formulation with shelf life below claim thresholds (to avoid dependent claims 3-5).
How does this patent sit in the broader NO-donor and topical dermatology landscape?
Without introducing external, uncited documents, the patent’s relative position can be described only in terms of its claim architecture. The landscape logic is:
-
This patent is technology-led (NO donor particle + specific vehicle).
- Many NO donor patents target wound healing, vascular disorders, or general NO-releasing compositions.
- Here, the claim anchors on a particular silica nanoparticle class and couples it to an alcohol/HPC/silicone anhydrous vehicle.
-
This patent is product-formulation led (stability and packaging features).
- Claims 3-5 add commercial product readiness constraints.
- Many earlier concepts may omit shelf-life and packaging performance as express limitations.
-
This patent is indication-led (acne treatment).
- Acne is a dermatology endpoint often tied to antibacterial effects and inflammation control.
- The patent uses the NO donor chemistry as the claimed therapeutic basis through method-of-use claim language.
In landscape terms, US 9,289,442 is most relevant to other filings that overlap in all three dimensions:
- DCD silica (or close equivalents),
- anhydrous alcohol topical vehicles with HPC/hexylene glycol/cyclomethicone,
- and dermatologic therapeutic use, particularly acne.
Freedom-to-operate drivers for R&D and investors
1) The “active identity” is the gate
The term “diazeniumdiolated co-condensed silica particle” is the highest-value discriminant. R&D teams should treat it as a hard boundary between:
- formulations that use this specific NO donor architecture, and
- formulations using different NO donor modalities or different silica architectures.
2) The “vehicle band” restricts formulation space
The alcohol range (45% to 95%) is a major boundary condition. It constrains solvent selection and the ability to maintain an anhydrous system.
3) Stability claims can constrain product development
Claims 3-5 create an enforceability lever tied to packaged shelf life. Stability testing, container compatibility, and storage condition control become essential.
Key Takeaways
- US 9,289,442 claims a specific anhydrous alcohol-based topical composition that must contain HPC, hexylene glycol, cyclomethicone, and diazeniumdiolated co-condensed silica particles within defined weight ranges.
- Claim 1 is the core: mandatory ingredient set + mandatory quantitative bands (HPC 0.1%-15%, alcohol 45%-95%, hexylene glycol 1%-20%, cyclomethicone 0.5%-15%, DCD silica 0.1%-40%).
- Claim 2 narrows with a particle size mean < 10 µm.
- Claims 3-5 add packaged shelf-life requirements (at least 4 weeks; refrigerated option; at least 52 weeks).
- Claims 6-7 provide method-of-use coverage for applying the claim 1 composition to treat dermatological conditions, including acne.
FAQs
-
Is the nitric oxide component claimed only by function?
No. The claims require “diazeniumdiolated co-condensed silica particle” by structural/chemical identity, not just generic NO donor function.
-
What single variable most constrains product design?
Alcohol content (45%-95%) combined with anhydrous status.
-
Can a formulation avoid claim 2 while still falling under claim 1?
Yes. Claim 2 is dependent; avoiding the <10 µm mean particle size can remove claim 2 coverage while potentially leaving claim 1 exposure if other elements match.
-
Do shelf-life limits matter only for storage?
They matter because they are explicit claim limitations in claims 3-5 tied to packaged shelf life and, in claim 4, refrigerated conditions.
-
Does the patent cover acne only, or other conditions too?
Claim 6 covers dermatological conditions generally, while claim 7 specifies acne.
References
[1] US Patent 9,289,442. “An anhydrous topical pharmaceutical composition…” (claims provided in prompt).
